XFOR Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -6.47%, SMA50 -12.52%, SMA200 1.61%). The stock’s 14-day RSI is 42.39 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -75.98% below its high and over 140.74% above its low. Average 10-day trading volume of 306.45 thousand shares is below the 3-month average of 497.46 thousand, indicating normal recent market interest.

X4 Pharmaceuticals, Inc. generated EPS of -$10.01 over the past year. Five-year average earnings growth is 47.41%. Wall Street analysts project EPS growth of 48.4% annually over the next five years. The latest quarter delivered EPS of -$0.22. The next quarter is forecast at -$0.25. Next year's EPS is expected at $34.15. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $3.50. The high target offers 185.04% upside. The low target suggests -16.86% downside. The mean target is $7.90. This offers 87.65% upside. X4 Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended March 17, 2026, missed forecasts by -38.89%. The prior quarter beat by 56.59%. Over the last six quarters, Apple has recorded several small beats. These include 5.88% in November 13, 2024.

X4 Pharmaceuticals, Inc. has 22.45 million shares outstanding. The public float is 8.16 million shares, elevated short interest at 6.95% of float. This equals 1.55 million shares. The short ratio is 0.17 days. Institutional investors hold 90.86% of the float. Insiders own 0.63%. SVLSF V, LLC holds 1.85 million shares, Ragan Paula has 1.09 million shares and Nessi Claudio has 867.64 thousand shares.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) closed at $4.21 USD, gaining $0.02 (0.48%) from the previous close of $4.19. The stock is currently mid-range between its 52-week high and low $1.35 and $4.83. With a market capitalization of about $48.03 million, X4 Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 488.69 thousand shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, X4 Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adam R. Craig, the company employs approximately 143 people and listed since November 16, 2017. X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.

X4 Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.61. This means the shares are trading above this model’s fair value.

X4 Pharmaceuticals, Inc. trades at a P/E ratio of -5.89, slightly below the S&P 500 average, with a price-to-sales ratio of 1.37 and a price-to-book ratio of 2.5 suggesting the stock is closer to book value. The P/FCF stands at -0.56, also below market averages.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) shares are flat -8.25% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows X4 Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -5.89. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.16, suggesting 70.07% upside. Our AI forecast model points to short-term weakness (-3.09% over two weeks), a medium-term fall (-69.83% over three months), and a longer-term gain (94.06% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that X4 Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.09%, with price expected at $4.08 by May 14, 2026, within a range of $3.85 to $4.34 3-Month Outlook: Projected fall of -69.83%, reaching $1.27 by July 29, 2026, with a range of $0.80 to $1.74. 1-Year Outlook: Projected gain of 94.06%, with price at $8.17 by April 30, 2027, within a range of $0.00 to $7.58.